網關基因組學

2023年5月31日

全球產前DNA測序市場預計將從18.4億年的2022美元增長到20.9億年的2023美元,複合年增長率(CAGR)的13.8%。產前DNA測序市場預計將增長到35.2億年的2027美元的CAGR為13.9%。癌症患病率的增加將推動產前DNA測序的增長市場。癌症是一種疾病,少數身體細胞生長失控和擴散到其他地區。產前DNA測序在癌症是用於檢測胎兒非整倍性胎兒在母親的血漿和識別癌症。DNA測序揭示了繼承或生殖係變化,提高人的患癌症的機會。例如,根據Globocan,瑞士提供全球癌症發病率和死亡率的數據庫,在2020年,有大約1929萬名新癌症病例,和癌症病例的數量在一個5年跨度估計為5055萬。因此,癌症的發病率是駕駛產前DNA測序市場。產品創新是一個關鍵的產前DNA測序市場的流行趨勢。大公司市場經營的重點是開發創新的解決方案,加強他們的市場地位。 For instance, in November 2022, Juno Diagnostics, Inc., a US-based health technology company that democratizes access to valuable genetic information, launched the noninvasive prenatal screening test "Hazel". The test is uniquely designed with no risk of miscarriage, and it can be performed as early as 9 weeks into pregnancy by using a small amount of blood. It screens the pregnancy for common genetic conditions caused by extra or missing chromosomes, such as Down syndrome, Edwards syndrome, and Patau syndrome. In November 2022, Myriad Genetics, Inc., a US-based provider of genetic testing and precision medicine acquired Gateway Genomics, LLC for an undisclosed amount. Myriad expects to expand and strengthen its portfolio of women's health products, as well as provide access to personalized genetic tests, with the combined resources of this acquisition. Gateway Genomics, LLC is a US-based personal genomics, and prenatal DNA company and a developer of consumer genetic tests. North America was the largest region in the prenatal DNA sequencing market in 2022. The regions covered in the prenatal DNA sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prenatal DNA sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Scope 1) By Type: Genetic Diseases; Nonhereditary Diseases 2) By Application: Hemophilia; Down Syndrome; Cystic Fibrosis; Autism; DiGeorgre Syndrome; AIDS (Acquired Immunodeficiency Syndrome); Cancer; Other Applications 3) By End User: Academic Research; Clinical Research; Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Other End Users Key Attributes: